Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism.

Department of Clinical Studies, Radiation Effects Research Foundation, 1-8-6 Nakagawa, Nagasaki 850-0013, Japan.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 08/2004; 89(7):3365-70. DOI: 10.1210/jc.2003-031089
Source: PubMed

ABSTRACT We investigated possible associations between subclinical hypothyroidism and atherosclerotic diseases (ischemic heart disease and cerebrovascular disease) and mortality. Of 2856 participants (mean age 58.5 yr) in a thyroid disease screening between 1984 and 1987, 257 subjects with subclinical hypothyroidism (TSH > 5.0 mU/liter) and 2293 control subjects (TSH range 0.6-5.0 mU/liter) were analyzed. In the baseline cross-sectional analysis, subclinical hypothyroidism was associated with ischemic heart disease independent of age, systolic blood pressure, body mass index, cholesterol, smoking, erythrocyte sedimentation rate, or presence of diabetes mellitus [odds ratio (OR), 2.5; 95% confidence interval (95% CI), 1.1-5.4 in total subjects and OR, 4.0; 95% CI, 1.4-11.5 in men] but not in women. However, there was no association with cerebrovascular disease (OR, 0.9; 95% CI, 0.4-2.4). We were unable to detect an influence of thyroid antibody presence on the association between subclinical hypothyroidism and ischemic heart disease. In a 10-yr follow-up study until 1998, increased mortalities from all causes in yr 3-6 after baseline measurement were apparent in men with subclinical hypothyroidism (hazard ratio, 1.9-2.1) but not in women, although specific causes of death were not determined. Our results indicate that subclinical hypothyroidism is associated with ischemic heart disease and might affect all-cause mortality in men.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The link between low thyroid hormone (TH) function and heart failure (HF) is reviewed. The idea that TH dysfunction may contribute to diseases leading to HF has been discussed for over 60 years. A growing body of evidence from animal and human studies, particularly in recent years, suggests that TH treatment may improve clinical outcomes. Indeed, if a similar amount of positive information were available for a newly developed heart drug, there is little doubt that large scale clinical trials would be underway with considerable excitement. THs offer the promise of improving ventricular contraction and relaxation, improving coronary blood flow, inhibiting atherosclerosis, and new results suggest they may even reduce the incidence of arrhythmias in heart diseases. Are the potential clinical benefits worth the risk of possible overdosing? After so many years, why has this question not been answered? Clearly, the concept has not been disproven. This review will explore the body of clinical evidence related to TH dysfunction and HF, discuss insight into pathophysiologic, cellular, and molecular mechanisms provided by animal research, and discuss what is needed to resolve this long-standing issue in cardiology and move forward.
    AJP Heart and Circulatory Physiology 11/2014; 308(1):ajpheart.00704.2014. DOI:10.1152/ajpheart.00704.2014 · 4.01 Impact Factor
  • Source
    Saudi medical journal 12/2014; 35(12):1469-76. · 0.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present study is to study the prevalence of subclinical hypothyroidism and its association with dyslipidemia. Thyroid hormone maintains the development and metabolism of the body. Thyroid dysfunction has been associated with complications like infertility, diastolic hypertension, ischemic heart disease, psychiatric disorders. 1157 sub-jects attending the NRI Hospital, Guntur for routine check up were taken into study. The patients were not under any medication. TSH and lipid profile was determined for all the subjects. The thyroid screening was done on Centaur CP and lipid profile on Dade Behring autoanalyzer. FT 4 was estimated in subjects with TSH level 5.5 to 10µIU/ml to confirm SCH. Result: The prevalence of Subclinical Hypothyroidism (SCH) was 8.29% and the SCH was associated with increased dyslipidemia. Total cholesterol, triglyceride, LDL were raised up to 317 mg/dl, 575mg/dl and 201mg/dl respectively. TSH level significantly correlated with total cholesterol and LDL cholesterol.

Full-text (2 Sources)

Available from
Jun 3, 2014

Similar Publications